SCHEMBL716858

SCHEMBL716858

CON(C)C(=O)c1oc2cc(F)ccc2c1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPT P10636 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NR1H2 P55055 1/20 0.45
MCL1 Q07820 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718499 0.89 MAPT (0.57) KDM4EALDH1A1MAPTSMN1; SMN2MCL1
SCHEMBL4653953 0.87 KDM4E (0.49) KDM4EALDH1A1MAPTMCL1CYP1A2
SCHEMBL4654264 0.83 ALDH1A1 (0.45) KDM4EALDH1A1MAPTSMN1; SMN2MCL1
SCHEMBL720540 0.81 HTT (0.54) KDM4EALDH1A1MAPTSMN1; SMN2L3MBTL1
SCHEMBL29545850 0.79 MCL1 (0.50) KDM4EALDH1A1MAPTSMN1; SMN2NR1H2
SCHEMBL4763051 0.79 MCL1 (0.67) KDM4EALDH1A1MAPTSMN1; SMN2NR1H2
SCHEMBL721535 0.79 PKM (0.58) KDM4EMAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL719607 0.77 MCL1 (0.63) KDM4EALDH1A1MAPTSMN1; SMN2MCL1
SCHEMBL20893409 0.76 KDM4E (0.52) KDM4EALDH1A1MAPTSMN1; SMN2NR1H2
SCHEMBL29546518 0.74 MCL1 (0.46) KDM4EALDH1A1MAPTSMN1; SMN2NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885MAPT 4533/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885MAPT 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.